Indeed, our data indicate limiting syndecan‐2 (by SDC2 knockdown or syndecan‐2 peptide overexpression) in TASCs attenuates TGFβ signalling within the breast TME reducing tumour growth and metastasis. The gene discussed is TGFB1; the disease is neoplasm.